{"id":60420,"date":"2024-02-28T06:48:16","date_gmt":"2024-02-28T06:48:16","guid":{"rendered":"https:\/\/medsname.com\/riscon\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"riscon","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/riscon\/","title":{"rendered":"Riscon"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Riscon?<\/h3>\n
\n

Riscon<\/strong> obsahuje risperidone<\/strong> from a WHO-GMP certified manufacturer (Sun Pharma) — one of the most-prescribed atypical antipsychotics<\/strong> worldwide. FDA-approved for schizophrenia (adults and adolescents 13+), bipolar mania (adults and ages 10+), and irritability in autism (children 5+). Mechanism: tight D2<\/sub> + 5-HT2A<\/sub> antagonism. Standard adult dose: 2–6 mg\/day<\/strong> (start 0.5–1 mg, titrate gradually). Distinctive side effects<\/strong>: highest hyperprolactinaemia<\/strong> of the atypicals (galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction); EPS at doses > 6 mg\/day (atypical \u2192 typical “crossover” behaviour); moderate metabolic burden. FDA black box for elderly dementia mortality<\/strong>.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

Important — this is not a situational-anxiety medication.<\/strong> Riscon is a atypical antipsychotic<\/strong>, prescribed and titrated over weeks for schizophrenia, bipolar mania, and irritability associated with autistic disorder in children<\/strong>. It is ne<\/strong> the right drug for acute, performance-related anxiety (flying, public speaking, exams) — for those use cases beta-blockers (propranolol), benzodiazepines, or hydroxyzine are clinically appropriate. If you do not have a diagnosed mood, anxiety, or psychiatric disorder, do not start this medication.<\/div>\n
FDA black-box warning — elderly dementia mortality.<\/strong> All antipsychotics (atypical and conventional) carry an FDA black-box warning for increased mortality when used to treat dementia-related psychosis or behavioural disturbance in elderly patients. This medication is not approved<\/strong> for dementia-related symptoms.<\/div>\n

What Is Riscon?<\/h2>\n

Riscon is an oral tablet of risperidone<\/strong> manufactured by Sun Pharma. Risperidone (US brand Risperdal<\/strong>) was launched by Janssen in 1993 and is one of the most-prescribed atypical antipsychotics globally. It is a tight D2<\/sub> and 5-HT2A<\/sub> antagonista<\/strong> with additional alpha-1, alpha-2, and H1<\/sub> blockade. Tighter D2<\/sub> binding than other atypicals means risperidone behaves more like a first-generation antipsychotic at higher doses — with EPS risk above 6 mg\/day. The active metabolite paliperidone (9-OH-risperidone) drives much of the clinical effect and is itself marketed separately as Invega.<\/p>\n

Schv\u00e1len\u00e9 indikace<\/h2>\n
    \n
  • Schizophrenia<\/strong> — adults and adolescents (age 13+)<\/li>\n
  • Bipolar mania (acute)<\/strong> — adults and children (age 10+); monotherapy or with lithium \/ valproate<\/li>\n
  • Irritability associated with autistic disorder<\/strong> — children (age 5+); aggression, self-injurious behaviour, severe tantrums<\/li>\n
  • Off-label: behavioural disturbance in dementia (use very carefully — black-box warning), Tourette syndrome, treatment-resistant depression, OCD augmentation<\/li>\n<\/ul>\n

    D\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n\n
    Indikace<\/th>\nStart<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u011b<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    Schizophrenia (adult)<\/td>\n1 mg BID or 2 mg HS<\/td>\n4–8 mg\/day<\/td>\n16 mg\/den<\/td>\nMost prescribers stay 2–6 mg\/day — EPS risk rises sharply above 6 mg\/day<\/td>\n<\/tr>\n
    Schizophrenia (adolescent 13+)<\/td>\n0.5 mg HS<\/td>\n3 mg\/day<\/td>\n6 mg\/day<\/td>\nStandard adolescent target<\/td>\n<\/tr>\n
    Bipolar mania (adult)<\/td>\n2–3 mg HS<\/td>\n1–6 mg\/day<\/td>\n6 mg\/day<\/td>\nOnce-daily HS dosing typical<\/td>\n<\/tr>\n
    Autism irritability (5–16 y, < 20 kg)<\/td>\n0.25 mg\/day<\/td>\n0.5–3 mg\/day weight-based<\/td>\n\u2014<\/td>\nSlow titration; reassess after 4–6 weeks<\/td>\n<\/tr>\n
    Star\u0161\u00ed pacienti<\/td>\n0.25–0.5 mg BID<\/td>\n1–2 mg\/day<\/td>\n\u2014<\/td>\nSignificant orthostasis and falls risk; black-box dementia warning<\/td>\n<\/tr>\n
    Jatern\u00ed\/ren\u00e1ln\u00ed selh\u00e1n\u00ed<\/td>\n0.5 mg BID<\/td>\nPomalej\u0161\u00ed titrace<\/td>\n\u2014<\/td>\nHalve usual dose increments<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

    Side-effect profile<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Frekvence<\/th>\n\u00da\u010dinek<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    B\u011b\u017en\u00e9<\/td>\nHyperprolaktin\u00e9mie<\/td>\nHighest of the atypicals — galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction; check prolactin if symptomatic<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nSedation, fatigue<\/td>\nModerate; less than quetiapine<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nP\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze<\/td>\nModerate (3–5 kg over 12 months)<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nOrthostatic hypotension<\/td>\nAlpha-1 blockade<\/td>\n<\/tr>\n
    Common (dose-dependent)<\/td>\nExtrapyramidal symptoms (akathisia, parkinsonism, dystonia)<\/td>\nHigher than other atypicals; significant above 6 mg\/day<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nAnticholinergic (dry mouth, constipation)<\/td>\nM\u00edrn\u00fd<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nMetabolic syndrome (glucose, lipids)<\/td>\nModerate — less than olanzapine \/ quetiapine; baseline + monitoring<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nTardive dyskinesia<\/td>\nLower than first-generation antipsychotics; risk increases with duration<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nProdlou\u017een\u00ed QT intervalu<\/td>\nMild — less than ziprasidone<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nNeuroleptic malignant syndrome<\/td>\nEmergency<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nStroke \/ TIA in elderly<\/td>\nBlack-box dementia warning<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Interakce s l\u00e9\u010divy<\/h2>\n

    CYP2D6 substrate<\/strong>: levels rise with strong inhibitors (paroxetine, fluoxetine, bupropion, quinidine) — reduce dose. CYP3A4 inducers (carbamazepine, rifampin, phenytoin) lower levels — need higher dose.<\/p>\n

    Additive sedation \/ orthostasis<\/strong>: alcohol, benzodiazepines, opioids, antihypertensives.<\/p>\n

    Prodlou\u017een\u00ed QT intervalu<\/strong>: caution with citalopram (high dose), ondansetron, methadone.<\/p>\n

    Anti-Parkinson medications<\/strong>: antagonism — risperidone D2<\/sub> blockade reduces dopaminergic effect of levodopa, ropinirole, pramipexole.<\/p>\n

    Hyperprolactinaemia — the Risperidone Concern<\/h2>\n

    Risperidone is the most prolactin-elevating atypical antipsychotic<\/strong>. The mechanism is tuberoinfundibular D2<\/sub> blockade in the pituitary, which removes dopamine’s normal inhibition of prolactin release. Clinical consequences:<\/p>\n